# Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

> **NCT06065462** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 21 (estimated)

## Conditions studied

- Ovarian Clear Cell Carcinoma

## Interventions

- **DRUG:** Dostarlimab
- **DRUG:** LB-100

## Key facts

- **NCT ID:** NCT06065462
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06065462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06065462, "Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06065462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*